|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED ANTICOAGULANT EFFECTS; THESE EFFECT MAY BE PRONOUNCED IN THE ELDERLY
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED ANTICOAGULANT EFFECTS; THESE EFFECT MAY BE PRONOUNCED IN THE ELDERLY
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ALCOHOL HAS VARIABLE EFFECT ON ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
OMEPRAZOLE DELAYS ELIMINATION OF THE DRUG
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
ALCOHOL HAS VARIABLE EFFECT ON ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ALPHATOCOPHERYL ACETATE IN HIGH DOSES MAY INCREASE THE EFFICACY OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
CO-ADMINISTRATION HAS RESULTED IN BLEEDING AND/OR INCREASED PROTHROMBIN TIME IN FEW PATIENTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED ANTICOAGULANT EFFECTS; THESE EFFECT MAY BE PRONOUNCED IN THE ELDERLY
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
OMEPRAZOLE DELAYS ELIMINATION OF THE DRUG
|
ENHANCED EFFECTS OF ANTICOAGULANT
|
ENHANCED EFFECTS OF ANTICOAGULANT
|
CO-ADMINISTRATION HAS RESULTED IN BLEEDING AND/OR INCREASED PROTHROMBIN TIME IN FEW PATIENTS
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
ANTICOAGULANT EFFECT IS REDUCED
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
|
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
GRISEOFULVIN DECREASES THE ACTIVITY OF WARFARIN-TYPE ANTICOAGULANTS
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
COUMARINE DERIVATIVES & NSAIDS EFFECT ON GI BLEEDING IS SYNERGISTIC, HENCE CO-ADMINISTRATION HAS HIGHER RISK OF BLEEDING
|
ANTICOAGULANT EFFECT IS REDUCED
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ALCOHOL HAS VARIABLE EFFECT ON ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|